A Review: Effect of Whole Body Vibration on Parkinson Disease

Usama Bin Yar
<span title="2022-02-22">2022</span> <i title="Zenodo"> Zenodo </i> &nbsp;
INTRODUCTION Parkinson's disease (PD) is a complicated, irreversible and debilitating neurodegenerative condition leading to progressive depletion of nigrostriary dopaminergic neurons leading to a loss of motor control (Hirsch, M. A., & Farley, B. G. 2009). PD is composed of motor and non-motor signs and effects. The clinical phase of PD also continues with non-motor signs, and patients are not typically diagnosed at this stage of the disorder. Diagnosis happens when there are strong and
more &raquo; ... ble motor signs, such as resting tremor, stiffness, weakened posture reflexes. At a greater point of disease development, they show an impairment due to bradykinesia, fatigue, balance and gait troubles with frequent falling (Chen, J. J. 2010). In addition, the dopaminergic side effects of treatments such as dykineasia are becoming more troublesome. In comparison, the more disease occurs, the decrease the safety and efficiency of pharmaceutical treatments. In addition, retaining a vital degree of versatility is important in order to prevent home care, lack of control and social interaction. The cause of PD is unclear and there is no treatment or prevention to date and this disorder mostly affects people over 50 years of age and raises prevalence and occurrence with age. As a result, the ageing of the general global population would lead to a drastic number of individuals living with PD (Dorsey, E. R. et al., 2007). The prevalence of the disease increases rapidly with age, around 17.4 in 100 000 people aged between 50 and 59 years to 93.1 in 100 000 people aged between 70 and 79 years, with either a lifetime chance of contracting the disease of 1.5 percent (De Rijk, M. C. et al., 1995). Medicated and non-medicated treatments are proposed to be able to relieve the effects of PD patients (Pahwa, R., & Lyons, K. E. 2010). Non-pharmacological therapies are commonly recommended for the control of impairments that do not lead to pharmacological care (Olanow, C. W. et [...]
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.5281/zenodo.6220234">doi:10.5281/zenodo.6220234</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/57nt73nzlnaqtp5mpft5zk7p5e">fatcat:57nt73nzlnaqtp5mpft5zk7p5e</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20220504234602/https://zenodo.org/record/6220234/files/844.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/64/66/6466642e6e92f9bfd52c43d9e8c25ad9864adc38.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.5281/zenodo.6220234"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> zenodo.org </button> </a>